The successful clinical translational of tests developed under our initiative will provide a personalized “dynamic staging” of prostate cancer that is not possible with current pathology, blood and imaging tests. They will improve the clinical management of prostate cancer patients at each stage of the disease, and have the real potential to positively impact patient outcomes and improve quality of life for those living with prostate cancer.
